Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells

Paolo Corradini, Claudia Voena, Corrado Tarella, Monica Astolfi, Marco Ladetto, Antonio Palumbo, Maria Teresa Van Lint, Andrea Bacigalupo, Alessandra Santoro, Maurizio Musso, Ignazio Majolino, Mario Boccadoro, Alessandro Pileri

Research output: Contribution to journalArticle

Abstract

Purpose: To describe molecular monitoring of minimal residual disease in patients with myeloma who have achieved complete remission (CR) after autologous or allogeneic transplantation of hematopoietic cells. Materials and Methods: Clonal markers based upon the rearrangement of immunoglobulin heavy-chain genes were generated far each patient and used for polymerase chain reaction (PCR) detection of residual myeloma cells. Fifty-one patients entered the program and 36 achieved CR. After transplantation, molecular monitoring was performed on 29 patients (15 autologous and 14 allogeneic transplants) who had molecular markers. Results: Our data show that molecular remissions are rarely achieved (7%) with high-dose chemotherapy followed by single or double autografting. In addition, virtually all peripheral blood progenitor cell and bone marrow samples contained residual myeloma cells, even when sample collection was scheduled after repeated courses of high- dose chemotherapy. All patients autografted with PCR-positive cells remain positive, and eight of 15 have relapsed. Two patients were autografted with PCR-negative cells: one is in clinical and molecular remission, and one relapsed 25 months after the transplant. In the allografting setting, a higher proportion of patients (50%) achieved molecular remission; there were two relapses, one in the PCR-positive group and one in the PCR-negative group. Conclusion: This is the first large study of molecular remissions in myeloma patients to use a PCR-based approach utilizing patient-specific tumor markers. The sizeable fraction of patients who achieved molecular remission after allografting with peripheral blood progenitor cells represents a promising finding in an incurable disease.

Original languageEnglish
Pages (from-to)208-215
Number of pages8
JournalJournal of Clinical Oncology
Volume17
Issue number1
Publication statusPublished - Jan 1999

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Corradini, P., Voena, C., Tarella, C., Astolfi, M., Ladetto, M., Palumbo, A., Van Lint, M. T., Bacigalupo, A., Santoro, A., Musso, M., Majolino, I., Boccadoro, M., & Pileri, A. (1999). Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells. Journal of Clinical Oncology, 17(1), 208-215.